Showing papers on "Pyrazole published in 1999"
TL;DR: The iodinated nature of this compound offers additional utility as a gamma-enriching SPECT (single photon emission computed tomography) ligand that may be useful in characterizing brain CB1 receptor binding in vivo.
Abstract: As a potent, specific antagonist for the brain cannabinoid receptor (CB1), the biarylpyrazole N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A; 1) was the lead compound for initiating studies designed to examine the structure-activity relationships of related compounds and to search for more selective and potent cannabimimetic ligands. A series of pyrazole derivatives was designed and synthesized to aid in the characterization of the cannabinoid receptor binding sites and also to serve as potentially useful pharmacological probes. Therapeutically, such compounds may have the ability to antagonize harmful side effects of cannabinoids and cannabimimetic agents. Structural requirements for potent and selective brain cannabinoid CB1 receptor antagonistic activity included (a) a para-substituted phenyl ring at the 5-position, (b) a carboxamido group at the 3-position, and (c) a 2,4-dichlorophenyl substituent at the 1-position of the pyrazole ring. The most potent compound of this series contained a p-iodophenyl group at the 5-position, a piperidinyl carboxamide at the 3-position, and a 2,4-dichlorophenyl group at the 1-position of the pyrazole ring. The iodinated nature of this compound offers additional utility as a gamma-enriching SPECT (single photon emission computed tomography) ligand that may be useful in characterizing brain CB1 receptor binding in vivo.
474 citations
Patent•
16 Jul 1999TL;DR: In this article, substituted pyrazole derivatives of general formula (I), wherein R?1, R2, R3? and A have the indicated meaning, were described and a method for the production of said derivatives and their use as medicaments was discussed.
Abstract: The present invention concerns novel substituted pyrazole derivatives of general formula (I), wherein R?1, R2, R3? and A have the indicated meaning. The invention also relates to a method for the production of said derivatives and to their use as medicaments, especially as medicaments for the treatment of cardiovascular diseases.
288 citations
Patent•
16 Jul 1999TL;DR: In this paper, substituted pyrazole derivatives of general formula (I), wherein substituents R?1, R2, R3?, A, X and Y have the indicated meaning, were used for the treatment of cardiovascular diseases.
Abstract: The present invention concerns substituted pyrazole derivatives of general formula (I), wherein substituents R?1, R2, R3?, A, X and Y have the indicated meaning. The invention also relates to a method for the production of said derivatives and to their use as medicaments, especially as medicaments for the treatment of cardiovascular diseases.
237 citations
Patent•
17 Nov 1999TL;DR: A class of pyrazole derivatives described for use in treating p38 kinase mediated disorders are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.
Abstract: A class of pyrazole derivatives described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.
182 citations
Journal Article•
122 citations
TL;DR: In this paper, three different heterocyclic amine additives, pyridine, 3-cyanopyridine and pyrazole, were compared in the methyltrioxorhenium (MTO) catalyzed epoxidation of olefins using aqueous hydrogen peroxide.
101 citations
TL;DR: A novel fluoropyrazole ribonucleoside has been shown to have significant anti-influenza activity in vitro and is compared and contrasted with the structurally-related compound ribavirin in attempts to identify factors having significant bearing on the mode of action of both compounds.
Abstract: A novel fluoropyrazole ribonucleoside has been shown to have significant anti-influenza activity in vitro. The compound is compared and contrasted with the structurally-related compound ribavirin in attempts to identify factors having significant bearing on the mode of action of both compounds.
86 citations
TL;DR: In this article, reaction of five (3-oxo-4,4, 4,4-trifluorobutanoyl)heterocycles with hydrazine hydrate under mild conditions gave the corresponding 3-heterocyclyl-5-hydroxy 5-trifi-oromethyl 4,5-dihydropyrazoles.
76 citations
Patent•
12 May 1999TL;DR: In this article, a 1,5-diaryl-substituted pyrazole compounds which correspond in structure to Formula (I), or a pharmaceutically acceptable salt thereof: wherein A is =N- or =CH-; and which inter alia, inhibit the activity of p38 MAP kinase.
Abstract: The present invention contemplates 1,5-diaryl-substituted pyrazole compounds which correspond in structure to Formula (I), or a pharmaceutically-acceptable salt thereof: wherein A is =N- or =CH-; and which inter alia, inhibit the activity of p38 MAP kinase. Also contemplated by the invention are processes for the preparation of the contemplated compounds and for the use of a contemplated compound in treating a mammalian host having a p38 kinase- or TNF-mediated disease.
76 citations
Patent•
03 Jun 1999TL;DR: In this article, 1-(4-aminophenyl) pyrazoles were substituted on the 3 and 5 positions of the pyrazole ring and on the amino group at the 4 position of the phenyl ring.
Abstract: 1-(4-aminophenyl)pyrazoles optionally substituted on the 3- and 5-positions of the pyrazole ring and on the amino group at the 4-position of the phenyl ring are disclosed and described, which pyrazoles inhibit IL-2 production in T-lymphocytes.
70 citations
Patent•
08 Apr 1999TL;DR: In this article, the authors proposed a formula having formula (I) for treating diseases that are prevented by or ameliorated with Interleukin-2, Interletin-4, or Interleuxin-5 production inhibitors.
Abstract: Compounds having formula (I) are useful for treating diseases that are prevented by or ameliorated with Interleukin-2, Interleukin-4, or Interleukin-5 production inhibitors.
TL;DR: In this paper, a class of electroluminescent pyrazole-based polymers have been synthesized and their electrolumeinescent properties have been demonstrated, and these materials show bright electrolUMinescence and promising properties for electroluminous applications.
Abstract: A novel class of electroluminescent pyrazole-based polymers have been synthesised and their electroluminescent properties have been demonstrated. These materials show bright electroluminescence and promising properties for electroluminescent applications.
TL;DR: The structure of 2 in the solid state has been determined by an X-ray diffraction study as discussed by the authors, and the geometry around the metal center could be described as a distorted octahedron with the two phosphorus atoms of the phosphines occupying apical positions.
TL;DR: It is demonstrated that the two complexes are isostructural, and the cytotoxic activity of both Pd and Pt complexes was checked for six different tumor cell lines and was lower than that of cisplatin.
TL;DR: In this paper, the crystal structure of 3, in which the two metal centres are bridged by the pyrazolate moiety of the pzbzth anion, has been determined.
Abstract: Ruthenium(II) complexes of composition [(bipy)2Ru(Hpzbzth)][ClO4]2·3H2O 1, [(bipy)2Ru(pzbzth)][ClO4]·2H2O 2, [(bipy)2Ru(pzbzth)Ru(bipy)2][ClO4]3·H2O 3, [(bipy)2Ru(H3pzbzim)][ClO4]2·2H2O 4 and [(bipy)2Ru(Hpzbzim)]·2H2O 5, where Hpzbzth = 3,5-bis(benzthiazol-2-yl)pyrazole, H3pzbzim = 3,5-bis(benzimidazol-2-yl)pyrazole and bipy = 2,2′-bipyridine, have been synthesized and characterized. The crystal structure of 3, in which the two metal centres are bridged by the pyrazolate moiety of the pzbzth anion, has been determined. The two RuN6 chromophores in this complex are separated by 4.723(3) A. From the significant down-field shift of the pyrazolate CH proton in 3 (8.92 ppm) with respect to 1 (7.78 ppm) and 4 (7.82 ppm), the involvement of S· · ·H(C)· · ·S type interaction in 3 has been proposed. The equilibrium constants of the species involving dissociation of the NH protons of the bridging ligand and the change in the oxidation state of ruthenium from +2 to +3 have been determined in acetonitrile–water (3∶2) by cyclic voltammetric and spectrophotometric methods. Redox titrations of complexes 1, 3 and 4 by cerium(IV) have revealed that the disappearence of the metal-to-ligand charge transfer band is accompanied by the appearence of the ligand-to-metal charge transfer band at higher wavelengths. In the case of 3, when 1 equivalent of cerium(IV) is added, the mixed-valence RuIIRuIII species is generated which exhibits an absorption maximum at 950 nm due to the intervalence-transfer transition. The luminescence spectral behaviour of complexes 1–4 has been examined in methanol–ethanol (1∶4) solution (at 300 K) as well as in glassy state (at 77 K).
TL;DR: The synthesis and acid base behavior of two series of 26-membered dioxatetraamine and hexaamine heterocyclophanes containing two nuclei of either pyrazole (4a and 6a) or 1-benzylpyrazole(4b and 6b), respectively, are reported in this paper.
Abstract: The synthesis and acid−base behavior of two series of 26-membered dioxatetraamine and hexaamine heterocyclophanes containing two nuclei of either pyrazole (4a and 6a) or 1-benzylpyrazole (4b and 6b), respectively, are reported. Dipodal (2 + 2) condensations of 3,5-pyrazoledicarbaldehyde 2a or its 1-benzyl derivative 2b with 1,5-diamino-3-oxapentane afford in both cases the stable Schiff bases 3a,b in 90% yield, which after reduction with NaBH4 gave 4a,b in 75% and 84% yield, respectively. Condensation of 2a with diethylenetriamine leads to a complex mixture containing imidazolidine isomers, which was reduced in situ to afford 6a in 30% yield. Condensation of 2b with the same amine gave the stable diimidazolidine derivative 5b, which after crystallization was isolated as a pure compound in 80% yield and fully identified from analytical and 1H and 13C NMR data as a constitutional isomer with both imidazolidine rings located at the side of the pyrazole closer to the benzylic substituents. Reduction of 5b wit...
Patent•
04 Nov 1999
TL;DR: In this paper, the authors describe 3-aryl or 3-hetero-aryl pyrazoles with 4,5(3,4)-bicyclic ring fusion which are inhibitors of protein kinase activity.
Abstract: This invention relates to certain 3-aryl or 3-heteroaryl pyrazoles with 4,5(3,4)-bicyclic ring fusion which are inhibitors of protein kinase activity, of which some are novel compounds, to pharmaceutical compositions containing these pyrazoles and to processes for preparing these pyrazoles.
TL;DR: In this paper, three bis-macrocycles 7, 10, 11, consisting of two cyclononane units with a N 3, N 2 S, and NS 2 donor set bridged by a pyrazole group, have been synthesized and their complexation potential studied.
Patent•
26 Apr 1999
TL;DR: In this article, the 3-Arylphenyl sulfide derivatives represented by general formula (I) and insecticides and miticides containing these derivatives as the active ingredient are described.
Abstract: 3-Arylphenyl sulfide derivatives represented by general formula (I) and insecticides and miticides containing these derivatives as the active ingredient, wherein R represents C2-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; B0 to B2 and B3 represent each hydrogen, halogeno, cyano, C1-4 haloalkyl, etc.; n is 0, 1 or 2; and Ar represents a phenyl, thiophene or pyrazole ring, etc.
Patent•
28 Apr 1999TL;DR: The present paper relates to certain pyrazole derivatives of Formula (I) that are p-38 MAP kinase inhibitors, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds as mentioned in this paper.
Abstract: The present invention relates to certain pyrazole derivatives of Formula (I) that are p-38 MAP kinase inhibitors, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.
TL;DR: In this article, C 60 -fused isoxazolines have been synthesized by using 1,3-dipolar cycloadditions of pyrazole nitrile oxides, generated in situ, to C 60 under thermal or focused microwave irradiation.
TL;DR: The syntheses of a number of different N-linked heterocyclic pyrazole replacements based on the structure 1 are described (compounds 3-12) as hD4 ligands and the best compound identified was 13 which has high affinity for hD 4 (5.2 nM) and >300-fold selectivity for h D4 receptors over hD2 and hD3 receptors.
Patent•
31 May 1999TL;DR: In this article, a compound of formula (I) or its pharmaceutically acceptable salt thereof, where the 4-(sulfonyl)phenyl and the 4-substituted phenyl are attached to ring atoms of ring A, which are adjacent to each other, is presented.
Abstract: This invention provides a compound of formula (I) or its pharmaceutically acceptable salt thereof, wherein A is partially unsaturated or unsaturated five membered heterocyclic, or partially unsaturated or unsaturated five membered carbocyclic, wherein the 4-(sulfonyl)phenyl and the 4-substituted phenyl in formula (I) are attached to ring atoms of Ring A, which are adjacent to each other; R1 is optionally substituted aryl or heteroaryl, with the proviso that when A is pyrazole, R1 is heteroaryl; R2 is C?1-4? alkyl, halo-substituted C1-4 alkyl, C1-4 alkylamino, C1-4 dialkylamino or amino; R?3, R4 and R5? are independently hydrogen, halo, C?1-4? alkyl, halo-substituted C1-4 alkyl or the like; or two of R?3, R4 and R5? are taken together with atoms to which they are attached and form a 4-7 membered ring; R?6 and R7? are independently hydrogen, halo, C?1-4? alkyl, halo-substituted C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino or N,N-di C1-4 alkylamino; and m and n are independently 1, 2, 3 or 4. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.
Patent•
29 Sep 1999TL;DR: The use of pyrazole derivatives as medicaments for treating cardiovascular diseases has been studied in this paper, which relates to novel heterocyclyl-methyl-substituted pyrazoles derivatives.
Abstract: The invention relates to novel heterocyclyl-methyl-substituted pyrazole derivatives, to methods for producing them and to their use as medicaments, especially as medicaments for treating cardiovascular diseases.
TL;DR: In this paper, the reaction of the corresponding N-allylic or N-methallylic compounds, primary or secondary amines, carbon monoxide and hydrogen in the presence of [Rh(cod)Cl]2 as catalyst via a one pot hydroformylation - amine condensation - reduction sequence is described.
TL;DR: In this article, the neutral ruthenium cyclopropenyl complex (3) was prepared by deprotonation of 2 by removing one phosphine ligand of 3 by CH3CN, yielding a diastereomeric mixture in a 4:1 ratio of the substitution product.
TL;DR: In this article, a bridging co-ordination of the ligand is found, interpreted as sterically enforced upon comparison with the structures for L ǫ = [MeB(3-Mepz)3] and [HB(3,5-Me2pz) 3].
Abstract: Tris(pyrazolyl)borate ligands were synthesized by a new route from MeBBr2 and pyrazole derivatives under very mild conditions at room temperature to give TlL complexes. For L = [MeB(3,5-Me2pz)3]– a bridging co-ordination of the ligand is found, interpreted as sterically enforced upon comparison with the structures for L = [MeB(3-Mepz)3]– and [HB(3,5-Me2pz)3]–.
TL;DR: In this article, a one-pot synthesis of 1-methyl- and 1-phenylpyrazole-3(5)-ethyl esters 2,3a-e by the cyclocondensation of β-alkoxyvinyl trichloromethyl ketones 1a − e with methyl and phenyl hydrazine hydrochloride under mild conditions, is reported.
TL;DR: The design and synthesis of novel benzoic acid mustard derivatives of distamycin A bearing one or more pyrazole rings replacing the pyrrole rings of the latter are described and in vitro and in vivo activities against L1210 leukemia are reported and discussed.